Erythromycin and Poor venous access - a phase IV clinical study of FDA data

Summary:

Poor venous access is reported as a side effect among people who take Erythromycin (erythromycin), especially for people who are male, 60+ old, also take Soliris, and have Catheter site infection.

The phase IV clinical study analyzes which people have Poor venous access when taking Erythromycin. It is created by eHealthMe based on reports of 12,069 people who have side effects when taking Erythromycin from the FDA, and is updated regularly.

What is Erythromycin?

Erythromycin has active ingredients of erythromycin. It is often used in acne. eHealthMe is studying from 12,563 Erythromycin users. Check the latest studies of Erythromycin.

What is Poor venous access?

Poor venous access is found to be associated with 676 drugs and 480 conditions by eHealthMe. Check the latest studies of Poor venous access.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

12,069 people reported to have side effects when taking Erythromycin.
Among them, 36 people (0.3%) have Poor venous access.

Could Erythromycin cause Poor venous access?

Among these 36 people:

What is the gender of people who have Poor venous access when taking Erythromycin? *

female: 41.67 %
male: 58.33 %

What is the age of people who have Poor venous access when taking Erythromycin? *

What are other drugs people take besides Erythromycin? *

Soliris: 16 people, 44.44%
Pantoprazole: 12 people, 33.33%
Metformin: 12 people, 33.33%
Ciprofloxacin: 10 people, 27.78%
Prednisone: 10 people, 27.78%
Hydrochlorothiazide: 8 people, 22.22%
Dicyclomine Hydrochloride: 8 people, 22.22%
Valsartan: 8 people, 22.22%
Inflectra: 8 people, 22.22%
Mesalamine: 8 people, 22.22%

What are other side effects people have besides Poor venous access? *

Cough: 24 people, 66.67%
Fatigue (feeling of tiredness): 18 people, 50.00%
Pain: 15 people, 41.67%
Lower Respiratory Tract Infection: 14 people, 38.89%
Catheter Site Pain: 13 people, 36.11%
Joint Pain: 13 people, 36.11%
High Blood Pressure: 13 people, 36.11%
The Flu (the flu is caused by an influenza virus): 12 people, 33.33%
Nausea And Vomiting: 11 people, 30.56%
Diarrhea: 11 people, 30.56%

What are the existing conditions these people have? *

Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 10 people, 27.78%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 10 people, 27.78%
Catheter Site Infection (infection at the site of insertion): 10 people, 27.78%
Back Pain: 7 people, 19.44%
Paroxysmal Nocturnal Haemoglobinuria (haemoglobin in the urine): 6 people, 16.67%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 11.11%
Asthma: 3 people, 8.33%
Hypersensitivity: 2 people, 5.56%
Cyclic Vomiting Syndrome (prolonged episodes of severe nausea, vomiting): 1 person, 2.78%

* Approximation only. Some reports may have incomplete information.

Do you take Erythromycin and have Poor venous access?

- Check whether Poor venous access is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Erythromycin:

Erythromycin (12,563 reports)

Browse all side effects of Erythromycin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Poor venous access:

Poor venous access (677 drugs)

Browse all the conditions that are associated with Poor venous access:

Poor venous access (480 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on erythromycin (the active ingredients of Erythromycin) and Erythromycin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.